In a group of 67 patients with anti-PD-1/PD-L1-refractory NSCLC (monotherapy, 34; combination therapy, 33), the most commonly reported AEs were rash and fatigue (21% each) with monotherapy and pruritus (36%) and fatigue (24%) with combination therapy; the confirmed ORR was 3% for monotherapy and 3% for combination therapy [131]. Here, PDCD1 is linked to non-small cell lung carcinoma.